Document:

Exhibit 4.5

 

DESCRIPTION OF THE REGISTRANT’S
SECURITIES REGISTERED PURSUANT TO

 SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

As of December 31,
2020, Sports Ventures Acquisition Corp. (“we,” “our,”
“us” or the “Company”) had the following three classes of securities registered under Section 12 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) its units, consisting of one Class A ordinary
share (as defined below) and one-third of one redeemable warrant (as defined below),
with each whole warrant entitling the holder thereof to purchase one Class A ordinary share (the “units”), (ii) its
Class A ordinary shares, $0.0001 par value per share (“Class A ordinary shares”), and (iii) its public warrants, with
each whole warrant exercisable for one Class A ordinary share for $11.50 (the “warrants”).

 

We
are a Cayman Islands exempted company (company number 366462) and our affairs are governed by our amended and restated memorandum
and articles of association, the Companies Law and common law of the Cayman Islands. Pursuant to our amended and restated memorandum
and articles of association, we are authorized to issue 500,000,000 Class A ordinary shares, $0.0001 par value each, 50,000,000
Class B ordinary shares, $0.0001 par value and 5,000,000 undesignated preference shares, $0.0001 par value each. The following
description summarizes the material terms of our share capital and does not purport to be complete. It is subject to, and
qualified in its entirety by reference to, our amended and restated memorandum
and articles of association, our amended and restated memorandum and articles of association and our warrant agreement,
each of which is incorporated by reference as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2020
(the “Report”) of which this Exhibit 4.5 is a part.

 

Defined terms used
herein but not otherwise defined shall have the meaning ascribed to such terms in the Report.

 

Units

 

Each unit consists of
one Class A ordinary share and one-third of one warrant. Each whole warrant entitles the holder thereof to purchase one
Class A ordinary share at a price of $11.50 per share. Warrants must be exercised for one whole Class A ordinary share.

 

Class A Ordinary Shares

 

Class A ordinary
shareholders and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be
voted on by shareholders and vote together as a single class, except as required by law; provided, that holders of our Class B
ordinary shares have the right to appoint all of our directors prior to our initial business combination and holders of our Class A
ordinary shares are not entitled to vote on the appointment of directors during such time. These provisions of our amended and
restated memorandum and articles of association may only be amended by a special resolution passed by at least 90% of our ordinary
shares voting in a general meeting. There is no cumulative voting with respect to the appointment of directors, with the result
that the holders of more than 50% of the founder shares voted for the appointment of directors can appoint all of the directors.
Our shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally
available therefor.

 

We will provide our
Class A public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of
our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the
trust account as of two business days prior to the consummation of our initial business combination, including interest (which
interest shall be net of taxes payable) divided by the number of then outstanding public shares, subject to the limitations described
herein. The redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem
its shares. Our initial holders, sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to waive their redemption rights with respect to their founder shares and public shares in connection with the
completion of our initial business combination.

 

If we seek shareholder
approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination
pursuant to the tender offer rules, our amended and restated memorandum and articles of association provide that a public shareholder,
together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group”
(as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than
an aggregate of 15% of the ordinary shares sold in our initial public offering, which we refer to as the “Excess Shares.”
However, our amended and restated memorandum and articles of association do not restrict our shareholders’ ability to vote
all of their shares (including Excess Shares) for or against our initial business combination. Our shareholders’ inability
to redeem the Excess Shares will reduce their influence over our ability to complete our initial business combination, and such
shareholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally,
such shareholders will not receive redemption distributions with respect to the Excess Shares if we complete the business combination.
And, as a result, such shareholders will continue to hold that number of shares exceeding 15% and, in order to dispose such shares
would be required to sell their shares in open market transactions, potentially at a loss.

 

     

    	 

    

 

In the event of a liquidation,
dissolution or winding up of the company after a business combination, our shareholders are entitled to share ratably in all assets
remaining available for distribution to them after payment of liabilities and after provision is made for each class of shares,
if any, having preference over the ordinary shares. Our shareholders have no preemptive or other subscription rights. There are
no sinking fund provisions applicable to the ordinary shares, except that we will provide our shareholders with the opportunity
to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account,
including interest (which interest shall be net of taxes payable) upon the completion of our initial business combination, subject
to the limitations described in the Report.

 

Redeemable Warrants

 

Each whole warrant entitles
the registered holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed
below, at any time commencing on January 8, 2022, or 30 days after the completion of our initial business combination. The
warrants will expire five years after the completion of our initial business combination, at 5:00 p.m., New York City time,
or earlier upon redemption or liquidation.

 

We are not obligated
to deliver any Class A ordinary shares pursuant to the exercise of a warrant and have no obligation to settle such warrant
exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the
warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below
with respect to registration, or a valid exemption from registration is available. No warrant is exercisable and we are not obligated
to issue a Class A ordinary share upon exercise of a warrant unless the Class A ordinary shares issuable upon such warrant
exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered
holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect
to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire
worthless. In no event will we be required to net cash settle any warrant. In the event that a registration statement is not effective
for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit
solely for the Class A ordinary share underlying such unit.

 

We have agreed that
as soon as practicable, but in no event later than 20 business days after the closing of our initial business combination, we will
use our commercially reasonable efforts to file with the SEC a registration statement for the Registration, under the Securities
Act, of the Class A ordinary shares issuable upon exercise of the warrants, and we will use our commercially reasonable efforts
to cause the same to become effective within 60 business days after the closing of our initial business combination, and to maintain
the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until
the warrants expire or are redeemed, as specified in the warrant agreement; provided that if our Class A ordinary shares are
at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of
a “covered security” under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of public
warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the
Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but
we will use our commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent
an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of
the warrants is not effective by the 60th day after the closing of the initial business combination, warrant holders
may, until such time as there is an effective registration statement and during any period when we will have failed to maintain
an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9)
of the Securities Act or another exemption, but we will use our commercially reasonably efforts to register or qualify the shares
under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price
by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained
by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess
of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value
and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the
Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise
is received by the warrant agent.

 

    2

    	 

    

 

Redemption of warrants
when the price per Class A ordinary share equals or exceeds $18.00.    Once the warrants become exercisable,
we may call the warrants for redemption (except as described herein in certain circumstances with respect to the placement warrants):

 

		●	in whole and not in part;

 

		●	at a price of $0.01 per warrant;

 

		●	upon not less than 30 days’ prior written
notice of redemption to each warrant holder; and

 

		●	if, and only if, the closing price of the Class A
ordinary shares equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations,
recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three trading days before we
send the notice of redemption to the warrant holders.

 

We will not redeem the
warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A
ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A
ordinary shares is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we
may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
state securities laws.

 

Redemption of warrants
when the price per Class A ordinary share equals or exceeds $10.00.    Once the warrants become exercisable,
we may redeem the outstanding warrants:

 

		●	in whole and not in part;

 

		●	at $0.10 per warrant upon a minimum of 30 days’
prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless
basis prior to redemption and receive that number of Class A ordinary shares determined by reference to the table below,
based on the redemption date and the “fair market value” of our Class A ordinary shares (as defined below) except
as otherwise described below;

 

		●	if, and only if, the closing price of our Class A
ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise
or the exercise price of a warrant) for any 20 trading days within the 30-trading day period ending three trading days
before we send the notice of redemption to the warrant holders; and

 

		●	if the closing price of the Class A ordinary
shares for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption
to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise
or the exercise price of a warrant), the placement warrants must also be concurrently called for redemption on the same terms
as the outstanding public warrants, as described above.

 

Beginning on the date
the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants on
a cashless basis. The numbers in the table below represent the number of Class A ordinary shares that a warrant holder will
receive upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the “fair
market value” of our Class A ordinary shares on the corresponding redemption date (assuming holders elect to exercise
their warrants and such warrants are not redeemed for $0.10 per warrant), determined for these purposes based on volume weighted
average price of our Class A ordinary shares during the 10 trading days immediately following the date on which the notice
of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption date precedes the
expiration date of the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair
market value no later than one business day after the 10-trading day period described above ends.

 

Pursuant to the warrant
agreement, references above to Class A ordinary shares shall include a security other than Class A ordinary shares into
which the Class A ordinary shares have been converted or exchanged for in the event we are not the surviving company in our
initial business combination. The numbers in the table below will not be adjusted when determining the number of Class A ordinary
shares to be issued upon exercise of the warrants if we are not the surviving entity following our initial business combination.

 

The share prices set
forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise
of a warrant or the exercise price of a warrant is adjusted as set forth under the heading “— Anti-dilution Adjustments”
below. If the number of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices in the column headings
will equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number
of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number
of shares deliverable upon exercise of a warrant as so adjusted. The number of shares in the table below shall be adjusted in
the same manner and at the same time as the number of shares issuable upon exercise of a warrant. If the exercise price of a warrant
is adjusted, (a) in the case of an adjustment pursuant to the fifth paragraph under the heading “— Anti-dilution

 

    3

    	 

    

 

Adjustments” below, the adjusted
share prices in the column headings will equal the unadjusted share price multiplied by a fraction, the numerator of which is the
higher of the Market Value and the Newly Issued Price as set forth under the heading “— Anti-dilution Adjustments”
and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to the second paragraph under the heading
“— Anti-dilution Adjustments” below, the adjusted share prices in the column headings will equal the
unadjusted share price less the decrease in the exercise price of a warrant pursuant to such exercise price adjustment.

 

	Redemption Date (period to expiration	 	 	Fair
Market Value of Class A Ordinary Shares
	 of warrants)	 	 	≤10.00	 	 	 	11.00	 	 	 	12.00	 	 	 	13.00	 	 	 	14.00	 	 	 	15.00	 	 	 	16.00	 	 	 	17.00	 	 	 	≥18.00	 
	60 months	 	 	0.261	 	 	 	0.281	 	 	 	0.297	 	 	 	0.311	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	57 months	 	 	0.257	 	 	 	0.277	 	 	 	0.294	 	 	 	0.310	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	54 months	 	 	0.252	 	 	 	0.272	 	 	 	0.291	 	 	 	0.307	 	 	 	0.322	 	 	 	0.335	 	 	 	0.347	 	 	 	0.357	 	 	 	0.361	 
	51 months	 	 	0.246	 	 	 	0.268	 	 	 	0.287	 	 	 	0.304	 	 	 	0.320	 	 	 	0.333	 	 	 	0.346	 	 	 	0.357	 	 	 	0.361	 
	48 months	 	 	0.241	 	 	 	0.263	 	 	 	0.283	 	 	 	0.301	 	 	 	0.317	 	 	 	0.332	 	 	 	0.344	 	 	 	0.356	 	 	 	0.361	 
	45 months	 	 	0.235	 	 	 	0.258	 	 	 	0.279	 	 	 	0.298	 	 	 	0.315	 	 	 	0.330	 	 	 	0.343	 	 	 	0.356	 	 	 	0.361	 
	42 months	 	 	0.228	 	 	 	0.252	 	 	 	0.274	 	 	 	0.294	 	 	 	0.312	 	 	 	0.328	 	 	 	0.342	 	 	 	0.355	 	 	 	0.361	 
	39 months	 	 	0.221	 	 	 	0.246	 	 	 	0.269	 	 	 	0.290	 	 	 	0.309	 	 	 	0.325	 	 	 	0.340	 	 	 	0.354	 	 	 	0.361	 
	36 months	 	 	0.213	 	 	 	0.239	 	 	 	0.263	 	 	 	0.285	 	 	 	0.305	 	 	 	0.323	 	 	 	0.339	 	 	 	0.353	 	 	 	0.361	 
	33 months	 	 	0.205	 	 	 	0.232	 	 	 	0.257	 	 	 	0.280	 	 	 	0.301	 	 	 	0.320	 	 	 	0.337	 	 	 	0.352	 	 	 	0.361	 
	30 months	 	 	0.196	 	 	 	0.224	 	 	 	0.250	 	 	 	0.274	 	 	 	0.297	 	 	 	0.316	 	 	 	0.335	 	 	 	0.351	 	 	 	0.361	 
	27 months	 	 	0.185	 	 	 	0.214	 	 	 	0.242	 	 	 	0.268	 	 	 	0.291	 	 	 	0.313	 	 	 	0.332	 	 	 	0.350	 	 	 	0.361	 
	24 months	 	 	0.173	 	 	 	0.204	 	 	 	0.233	 	 	 	0.260	 	 	 	0.285	 	 	 	0.308	 	 	 	0.329	 	 	 	0.348	 	 	 	0.361	 
	21 months	 	 	0.161	 	 	 	0.193	 	 	 	0.223	 	 	 	0.252	 	 	 	0.279	 	 	 	0.304	 	 	 	0.326	 	 	 	0.347	 	 	 	0.361	 
	18 months	 	 	0.146	 	 	 	0.179	 	 	 	0.211	 	 	 	0.242	 	 	 	0.271	 	 	 	0.298	 	 	 	0.322	 	 	 	0.345	 	 	 	0.361	 
	15 months	 	 	0.130	 	 	 	0.164	 	 	 	0.197	 	 	 	0.230	 	 	 	0.262	 	 	 	0.291	 	 	 	0.317	 	 	 	0.342	 	 	 	0.361	 
	12 months	 	 	0.111	 	 	 	0.146	 	 	 	0.181	 	 	 	0.216	 	 	 	0.250	 	 	 	0.282	 	 	 	0.312	 	 	 	0.339	 	 	 	0.361	 
	9 months	 	 	0.090	 	 	 	0.125	 	 	 	0.162	 	 	 	0.199	 	 	 	0.237	 	 	 	0.272	 	 	 	0.305	 	 	 	0.336	 	 	 	0.361	 
	6 months	 	 	0.065	 	 	 	0.099	 	 	 	0.137	 	 	 	0.178	 	 	 	0.219	 	 	 	0.259	 	 	 	0.296	 	 	 	0.331	 	 	 	0.361	 
	3 months	 	 	0.034	 	 	 	0.065	 	 	 	0.104	 	 	 	0.150	 	 	 	0.197	 	 	 	0.243	 	 	 	0.286	 	 	 	0.326	 	 	 	0.361	 
	0 months	 	 	—	 	 	 	—	 	 	 	0.042	 	 	 	0.115	 	 	 	0.179	 	 	 	0.233	 	 	 	0.281	 	 	 	0.323	 	 	 	0.361	 

  

The exact fair market
value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values
in the table or the redemption date is between two redemption dates in the table, the number of Class A ordinary shares to
be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set
forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or 366-day year,
as applicable. For example, if the volume weighted average price of our Class A ordinary shares during the 10 trading days
immediately following the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and
at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption
feature, exercise their warrants for 0.277 Class A ordinary shares for each whole warrant. For an example where the exact
fair market value and redemption date are not as set forth in the table above, if the volume weighted average price of our Class A
ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders
of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may
choose to, in connection with this redemption feature, exercise their warrants for 0.298 Class A ordinary shares for each
whole warrant. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for
more than 0.361 Class A ordinary shares per warrant (subject to adjustment). Finally, as reflected in the table above, if
the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis in connection with a redemption
by us pursuant to this redemption feature, since they will not be exercisable for any Class A ordinary shares.

 

    4

    	 

    

 

This redemption feature
differs from the typical warrant redemption features used in many other blank check offerings, which typically only provide for
a redemption of warrants for cash (other than in certain circumstances with respect to the placement warrants) when the trading
price for the Class A ordinary shares exceeds $18.00 per share for a specified period of time. This redemption feature is
structured to allow for all of the outstanding warrants to be redeemed when the Class A ordinary shares are trading
at or above $10.00 per public share, which may be at a time when the trading price of our Class A ordinary shares is below
the exercise price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the
warrants without the warrants having to reach the $18.00 per share threshold. Holders choosing to exercise their warrants in connection
with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing
model with a fixed volatility input as of January 5, 2021. This redemption right provides us with an additional mechanism by which
to redeem all of the outstanding warrants, and therefore have certainty as to our capital structure as the warrants would no longer
be outstanding and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant
holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants
if we determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is
in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.

 

As stated above, we
can redeem the warrants when the Class A ordinary shares are trading at a price starting at $10.00, which is below the exercise
price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant
holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to
redeem the warrants when the Class A ordinary shares are trading at a price below the exercise price of the warrants, this
could result in the warrant holders receiving fewer Class A ordinary shares than they would have received if they had chosen
to wait to exercise their warrants for Class A ordinary shares if and when such Class A ordinary shares were trading
at a price higher than the exercise price of $11.50.

 

No fractional Class A
ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in
a share, we will round down to the nearest whole number of the number of Class A ordinary shares to be issued to the holder.
If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares pursuant
to the warrant agreement (for instance, if we are not the surviving company in our initial business combination), the warrants
may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class A
ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities
Act the security issuable upon the exercise of the warrants.

 

Anti-dilution Adjustments.    The
warrants have certain anti-dilution and adjustments rights upon certain events.

 

The warrants were issued
in registered form under a warrant agreement between Continental, as warrant agent, and us. The warrant agreement provides that
the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or
correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the warrants
and the warrant agreement set forth in our prospectus, or defective provision (ii) amending the provisions relating to cash
dividends on ordinary shares as contemplated by and in accordance with the warrant agreement or (iii) adding or changing any
provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may
deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants,
provided that the approval by the holders of a majority of the then-outstanding public warrants is required to make any change
that adversely affects the interests of the registered holders. You should review a copy of the warrant agreement, which was filed
as an exhibit to our Current Report on Form 8-K on January 8, 2021, for a complete description of the terms and conditions applicable
to the warrants.

 

 

5Exhibit 10.10

 

IN ACCORDANCE WITH ITEM 601(b)(10)
of REGULATION S-K, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 10.10 BECAUSE IT IS BOTH NOT MATERIAL AND
IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This EXECUTIVE EMPLOYMENT
AGREEMENT (this “Agreement”) is made as of May 11, 2020 by and between CorMedix Inc., a Delaware corporation
(the “Company”), and Dr. Matt David (“Executive”). Each of the Company and
Executive is referred to herein as a “Party” and together they are referred to as the “Parties.”

 

TERMS

 

In consideration of
the foregoing premises and the mutual covenants and agreements herein contained, the Parties, intending to be legally bound, agree
as follows:

 

1. Employment.

 

(a) Services.
Executive will serve as the Company’s Executive Vice President and Chief Financial Officer. Executive will report directly
to, and be subject to the supervision of, the Company’s Chief Executive Officer (the “CEO”). Executive
will perform such services for the Company and have such powers, responsibilities and authority as are customarily associated with
the position of Executive Vice President and Chief Financial Officer and shall perform customary and appropriate duties as may
otherwise be reasonably assigned to the Executive from time to time by the CEO. The Parties anticipate that the Executive’s
first day of employment with the Company will be on May 11, 2020 (the first day of employment with the Company is referred to as
the “Commencement Date”).

 

(b) Acceptance.
Executive hereby accepts such employment subject to the terms of this Agreement.

 

2. Term.

 

The duration of employment
under this Agreement shall commence on the Commencement Date and shall continue for a term of three (3) years thereafter, unless
sooner terminated pursuant to Section 8 (such three-year period referred to herein as the “Initial Term”);
provided, however, that on the expiration of the Term, the Term shall be extended automatically for additional, successive
one-year periods (such extended periods referred to herein as the “Extended Term”), unless one Party
shall notify the other in writing at least ninety (90) days before the initial expiration of the Initial Term or the expiration
of any successive one-year period during the Extended Term that this Agreement shall not be so extended after such expiry (a “Notice
of Nonrenewal”). The Initial Term and the Extended Term collectively shall be referred to herein as the “Term.”
Notwithstanding anything to the contrary contained herein, the provisions of this Agreement specified in Sections 5, 6, 9,
10, 11, 12, and 13 shall survive the expiration or termination hereof. Notwithstanding anything in this Agreement to the
contrary, this Agreement shall be contingent on the Company receiving satisfactory results of Executive’s California criminal
background check (which has been delayed because of COVID-19 court closures), as determined in good faith by the Company’s
Board of Directors (the “Board”), and this Agreement shall immediately terminate without liability to
the Company in the event the Company does not receive such satisfactory results.

 

    1

     

    

 

3. Duties;
Place of Performance.

 

(a) Duties.
Except as otherwise set forth in this Section 3(a), Executive (i) shall devote all of his business time, attention and energies
to the business and affairs of the Company, shall use his best efforts to advance the interests of the Company, and shall perform
his duties diligently and to the best of his ability, in compliance with the Company’s policies and procedures and the laws
and regulations that apply to the Company’s business; and
(ii) shall not be engaged in any other business activity, whether or not such business activity is pursued for gain, profit or
other pecuniary advantage, that will interfere with the performance by Executive of his duties hereunder or Executive’s availability
to perform such duties or that Executive knows, or should reasonably know, will adversely affect, or negatively reflect upon, the
Company. With the advance written consent of the Board, Executive may serve as a director of, or on the advisory committee of,
other pharmaceutical and life science companies. Approval for any such business activity shall not be unreasonably withheld by
the Board, so long as the activity is not competitive with the business of the Company and does not interfere with the performance
of Executive’s duties hereunder.

 

(b) Place
of Performance. The duties to be performed by Executive hereunder shall be performed primarily at the executive offices of
the Company in Berkeley Heights, New Jersey, or wherever the principal executive offices of the Company shall hereafter be located,
subject to reasonable travel requirements on behalf of the Company, or such other place as the Company may reasonably designate.
The parties acknowledge that Executive may perform his duties remotely during the COVID-19 pandemic, as reasonably determined by
Executive and the Company.

 

4. Compensation.

 

As full compensation
for Executive’s performance of services as an employee of the Company, the Company shall pay Executive as follows:

 

(a) Base
Salary. During the Initial Term, the Company shall pay Executive an annual base salary of three hundred thirty thousand dollars
($330,000) (as it may be increased from time to time as provided hereunder, the “Base Salary”), less
applicable withholdings and deductions. Payment shall be made in accordance with the Company’s normal payroll practices.
Upon the expiration of the Initial Term, the Board, or its Compensation Committee, shall review the Base Salary to determine whether
an increase in the amount thereof is warranted in its sole discretion. The Base Salary will not be decreased unless (i) all officers
and/or members of the Company’s executive management team experience an equal or greater percentage reduction in annual base
salary and/or total compensation; and (ii) Executive’s Base Salary reduction is no greater than twenty-five percent
(25%).

 

(b) Annual
Bonus. Subject to the following provisions of this Section 4(b), Executive shall be eligible for an annual bonus,
less applicable withholdings and deductions, based upon a target amount of thirty percent (30%) of the Base Salary then in effect,
as determined by the Board (or its Compensation Committee) in good faith based upon the achievement, during the year in question,
of corporate objectives for the Company as a whole established by the Board (or its Compensation Committee) and such other factors
as the Board (or its Compensation Committee) deems appropriate. Executive must be employed by the Company through December 31 of
a given year in order to be eligible to earn the annual bonus for such year. The annual bonus for a given year will be paid no
later than March 15 of the year following the year to which it relates.

 

    2

     

    

 

(c) Equity
Grants.

 

(i) Initial
Stock Option Grant. As of the Commencement Date, the Board (or its Compensation Committee) shall approve the Company’s
grant to Executive of stock options to purchase two hundred fifty thousand (250,000) shares of the Company’s outstanding
common stock (the “Initial Options”). The Initial Options shall be granted pursuant to and subject to
the terms and conditions of the stock option agreements to be entered into between Executive and the Company. The Initial Options
will be divided into “Time Options” and “Milestone Options” as described below.

 

(1) 
The “Time Options” will be one hundred sixty six thousand (166,000) of the total Options, and will vest
over four (4) years in four (4) equal annual installments beginning one year after the applicable date of grant and continuing
on each of the next three (3) anniversaries of the applicable date of grant, subject to Executive’s continued employment
with the Company. The exercise price of eighty three thousand (83,000) of the Time Options will be five dollars and sixty-three
cents ($5.63) per share, or if higher, the closing price of the Company’s common stock on the New York Stock Exchange (the
“Fair Market Value”) on the applicable date of grant. The exercise price of the remaining eighty three
thousand (83,000) Time Options will be the Fair Market Value on the applicable date of grant.

 

(2) The
“Milestone Options” will consist of the remaining eighty four thousand (84,000) of the total Options,
and will vest based on achievement of the performance milestones described in the attached Exhibit A. The exercise price
of forty two thousand (42,000) of the Milestone Options will be five dollars and sixty-three cents ($5.63), or if higher, the Fair
Market Value on the applicable date of grant. The exercise price of the remaining forty two thousand (42,000) Milestone Options
will be the Fair Market Value on the applicable date of grant.

 

(ii) Annual
Equity Grants. Each year during the Term, commencing in 2021, the Board (or its Compensation Committee) will make an annual
equity grant to Executive, which may include restricted stock or restricted stock units (“Awards”) or
options to purchase shares of capital stock of the Company (“Stock Options”), with time-based or performance-based
vesting, in such amounts and on such terms as the Board (or its Compensation Committee) deems appropriate.

 

(d) Withholding.
The Company will withhold from any amounts payable under this Agreement such federal, state and local taxes as the Company determines
are required to be withheld pursuant to applicable law.

 

(e) 
Expenses. The Company shall reimburse Executive for all normal, usual and necessary expenses incurred by Executive in furtherance
of the business and affairs of the Company, including without limitation reasonable travel, lodging, meals, and entertainment,
upon timely receipt by the Company of appropriate vouchers or other proof of Executive’s expenditures and otherwise in accordance
with any expense reimbursement policy as may from time to time be adopted by the Company. Such reimbursements will be made in a
timely manner and in accordance with the policies of the Company, but in no event later than December 31 of the year following
the year in which Executive incurs such expense. The amount of expenses eligible for reimbursement during one year will not affect
the expenses eligible for reimbursement in any other year, and is not subject to liquidation or exchange for another benefit.

 

(f) Other
Benefits. Executive shall be entitled to all rights and benefits for which he shall be eligible under any benefit or other
plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock
purchase plans, profit sharing plans, bonus plans, prescription drug reimbursement plans, short and long term disability plans,
life insurance and other so-called “fringe” benefits) as the Company shall make available to its senior executives
from time to time. All such benefits are subject to the provisions of their respective plan documents in accordance with their
terms and are subject to amendment or termination by the Company without Executive’ s consent.

 

    3

     

    

 

(g) Vacation.
Executive shall be entitled to a vacation up to four (4) weeks per annum, of which no more than two (2) weeks may be taken consecutively,
in addition to holidays observed by the Company and reasonable periods of paid personal and sick leave. All such paid time off
shall accrue and be used in accordance with the Company’s established policies and procedures.

 

5. Confidential
Information and Inventions.

 

(a) Confidential
Information; Non-Disclosure and Non-Use. Executive recognizes and acknowledges that in the course of his duties he will
receive confidential or proprietary information of the Company, its affiliates or third parties with whom the Company or any such
affiliates has an obligation of confidentiality. Accordingly, during and after the Term, Executive agrees to keep confidential
and not disclose or make accessible to any other person or use for any other purpose other than in connection with the fulfillment
of his duties under this Agreement, any “Confidential and Proprietary Information” (defined below) owned by, or received
by or on behalf of the Company or any of its affiliates. The term “Confidential and Proprietary Information”
shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data, formulas and
related concepts, business plans (both current and under development), client lists, promotion and marketing programs, trade secrets,
or any other confidential or proprietary business information relating to development programs, costs, revenues, marketing, investments,
sales activities, promotions, credit and financial data, manufacturing processes, financing methods, and any and all information
relating to the operation of the Company’s business which the Company may from time to time designate as confidential or
proprietary or that Executive reasonably knows should be, or has been, treated by the Company as confidential or proprietary. Executive
expressly acknowledges that the Confidential and Proprietary Information constitutes a protectable business interest of the Company.
Confidential and Proprietary Information encompasses all formats in which information is preserved, whether electronic, print,
or any other form, including all originals, copies, notes, or other reproductions or replicas thereof. Executive agrees: (i) not
to use any such Confidential and Proprietary Information for himself or others; and (ii) not to take any Company material
or reproductions (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and business
policies, computer programs or disks) thereof from the Company’s offices at any time during his employment by the Company,
except in connection with the execution of Executive’s duties to the Company.

 

(b) Return
of Property. Upon request during employment and immediately at the termination of his employment, Executive will return to
the Company all Confidential and Proprietary Information in any form (including all copies and reproductions thereof) and all other
property whatsoever of the Company in his possession or under his control. If requested by the Company, Executive will certify
in writing that all such materials have been returned to the Company. Executive also expressly agrees that immediately upon the
termination of his employment with the Company for any reason, Executive will cease using any secure website, computer systems,
e-mail system, phone system or voicemail service provided by the Company for the use of its employees. Notwithstanding the foregoing,
Executive may retain his address book to the extent it only contains contact information.

 

(c) Exceptions.
Confidential and Proprietary Information does not include any information that: (i) at the time of disclosure is generally known
to, or readily ascertainable by, the public; (ii) becomes known
to the public through no fault of Executive or other violation of this Agreement;
or (iii) is disclosed to Executive by a third party under no obligation to Executive’s knowledge to maintain the confidentiality
of the information. The restrictions in Section 5(a) above will not apply to any information the extent that that
Executive is required to disclose such information by law, provided that the Executive (x) notifies the Company of the existence
and terms of such obligation, (y) gives the Company prompt notice to seek a protective or similar order to prevent or limit such
disclosure, and (z) only discloses that information actually required to be disclosed. Notwithstanding the foregoing, nothing in
this Agreement is meant to prohibit Executive from reporting possible violations of federal law or regulation to any governmental
agency or entity, including but not limited to the Department of Justice, the SEC, the Congress, and any agency Inspector General,
or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. Executive shall
not be required to obtain the prior authorization of the Company to make any such reports or disclosures and is not required to
notify the Company that he has made such reports or disclosures.

 

    4

     

    

 

(d) Notice
Of Immunity From Liability For Confidential Disclosure Of A Trade Secret To The Government Or In A Court Filing. Pursuant to
the Federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state or local government
official, either directly or indirectly, or to an attorney; and
(ii) solely for the purpose of reporting or investigating a suspected violation of law;
or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade
secret to his attorney and use the trade secret information in the court proceeding, if the individual (a) files any document containing
the trade secret under seal; and (b) does not disclose the trade
secret, except pursuant to court order.

 

(e) Inventions.
Executive agrees that all inventions, discoveries, improvements and patentable or copyrightable works (“Inventions”)
initiated, conceived or made by him within the scope of the Company’s business and in the course of his employment with the
Company, either alone or in conjunction with others, during the Term shall be the sole property of the Company to the maximum extent
permitted by applicable law and, to the extent permitted by law, shall be “works made for hire” as that term is defined
in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be the sole owner of all patents, copyrights,
trade secret rights, and other intellectual property or other rights in connection therewith;
provided, however that this Section 5(e) shall not apply to Inventions which are not related to the business
of the Company and which are made and conceived by Executive not during normal working hours, not on the Company’s premises
and not using the Company’s tools, devices, equipment or Confidential and Proprietary Information. Subject to the foregoing,
Executive hereby assigns to the Company all right, title and interest he may have or acquire in all Inventions;
provided, however, that the Board may in its sole discretion agree to waive the Company’s rights pursuant to this
Section 5(e).

 

(f) Further
Actions and Assistance. Executive agrees to cooperate reasonably with the Company and at the Company’s expense, both
during and after his employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents,
trademarks and other intellectual property rights (both in the United States and foreign countries) relating to the Inventions.
Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths,
formal assignments, assignments of priority rights and powers of attorney, that the Company reasonably may deem necessary or desirable
in order to protect its rights and interests in any Inventions. Executive further agrees that if the Company is unable, after reasonable
effort, to secure Executive’s signature on any such papers, any officer of the Company shall be entitled to execute such
papers as his agent and attorney-in-fact and Executive hereby irrevocably designates and appoints each officer of the Company as
his agent and attorney-in-fact to execute any such papers on his behalf and to take any and all actions as the Company reasonably
may deem necessary or desirable in order to protect its rights and interests in any Inventions, under the conditions described
in this Section 5(f).

 

(g) Prior
Inventions. Executive will not assert any rights to any invention, discovery, idea or improvement relating to the business
of the Company or to his duties hereunder as having been made or acquired by Executive prior to his work for the Company, except
for the matters, if any, described in Exhibit B to this Agreement.

 

    5

     

    

 

(h) Disclosure.
Executive agrees that he will promptly disclose to the Company all Inventions initiated, made, conceived or reduced to practice
by him, either alone or jointly with others, during the Term.

 

(i) Survival.
The provisions of this Section 5 shall survive any termination of this Agreement.

 

6. Non-Competition,
Non-Solicitation and Non-Disparagement.

 

(a) Executive
understands and recognizes that his services to the Company are special and unique and that in the course of performing such services
Executive will have access to and knowledge of Confidential and Proprietary Information. Executive agrees that, during the Term
and the twelve (12) month period immediately following Executive’s separation from employment (the “Termination
Restriction Period”), whether such separation is voluntary or involuntary, he shall not in any manner, directly or
indirectly, on behalf of himself or any person, firm, partnership, joint venture, corporation or other business entity (“Person”),
enter into or engage in any business involving the development or commercialization of a preventive anti-infective product that
would be a competitor of Neutrolin or a product containing taurolodine or any other product being actively developed or produced
by the Company as of the date of Executive’s termination of employment (the “Business of Company”),
either as an individual for his own account, or as a partner, joint venturer, owner, executive, employee, independent contractor,
principal, agent, consultant, salesperson, officer, director or shareholder of such Person, in any capacity that requires or could
result in Executive’s intentional or unintentional use of the Confidential and Proprietary Information and/or requires Executive
to perform services substantially similar to those performed for the benefit of the Company during the Term, anywhere in the world,
provided, however, that nothing shall prohibit Executive from performing executive duties for any Person that does not engage in
the Business of Company. Executive acknowledges that, due to the unique nature of the Business of the Company, the Company has
a strong legitimate business interest in protecting the continuity of its business interests and its Confidential and Proprietary
Information and the restriction herein agreed to by Executive narrowly and fairly serves such an important and critical business
interest of the Company. Notwithstanding the foregoing, nothing contained in this Section 6(a) shall be deemed to
prohibit Executive from acquiring or holding, solely for investment, publicly traded securities of any corporation, some or all
of the activities of which are engaged in the Business of Company so long as such securities do not, in the aggregate, constitute
more than four percent (4%) of any class or series of outstanding securities of such corporation;
or being a passive investor holding less than four percent (4%) of a private equity, venture capital or other commingled
fund; and further notwithstanding the foregoing, nothing contained
in this Section 6(a) shall preclude Executive from becoming an employee of, or from otherwise providing services
to, a separate division or operating unit of a multi-divisional business or enterprise (a “Division”)
if: (i) the Division by which Executive is employed, or to which Executive provides services, is not engaged in the Business of
Company, (ii) Executive does not provide services, directly or indirectly, to any other division or operating unit of such multi-divisional
business or enterprise engaged in or proposing to engage in the Business of Company (individually, a “Competitive Division”
and collectively, the “Competitive Divisions”) and (iii) the Competitive Divisions, in the aggregate,
accounted for less than one-third of the multi-divisional business or enterprise’s consolidated revenues for the fiscal year,
and each subsequent quarterly period, prior to Executive’s commencement of employment with or provision of services to the
Division.

 

    6

     

    

 

(b) Reasonableness
of Restriction. Executive hereby acknowledges and agrees that the covenant against competition provided for pursuant to Section
6(a) is reasonable with respect to its duration, geographic area and scope. In addition, Executive acknowledges that the
Company engages in the Business of Company throughout the world, and Executive has been involved in the Business of the Company
in that geographic area. If, at the time of enforcement of this Section 6, a court holds that the restrictions stated
herein are unreasonable under the circumstances then existing, the Parties hereto agree that the maximum duration, scope or geographic
area legally permissible under such circumstances will be substituted for the duration, scope or area stated herein.

 

(c) Non-Solicitation.
During the Term and the applicable Termination Restriction Period (as defined below), Executive shall not, directly or indirectly,
on his own behalf or on behalf of any person or entity, without the prior written consent of the Company:

 

(i) solicit
or induce any employee, consultant or independent contractor of the Company or any of its affiliates to leave the employ of (or
end a contracting relationship with) the Company or any affiliate; or
hire for any competitive purpose any employee consultant or independent contractor of the Company;
or hire any former employee who has left the employment of the Company or any affiliate of the Company within six (6) months
of the termination of such employee’s employment with the Company or any such affiliate for any competitive purpose;
or hire any former consultant or independent contractor who has ended his or her consultancy or contracting relationship
with the Company or any affiliate of the Company within six (6) months of the end of such consultancy or contracting relationship
for any competitive purpose; or hire any former employee of the
Company in knowing violation of such employee’s non-competition agreement with the Company or any such affiliate;
or

 

(ii) solicit,
divert or take away, or attempt to divert or take away, the business or patronage of any agent, client or customer of the Company
which was served by the Company during the twelve (12) -month period prior to the termination of Executive’s employment with
the Company; or induce, encourage, or attempt to induce or encourage
any client or customer of the Company which was served by the Company during the twelve (12) -month period prior to the termination
of Executive’s employment with the Company to reduce, limit, or cancel its business with the Company.

 

For clarity, the foregoing shall not be
violated by general advertising, by serving as a reference upon request or by actions taken in the good faith performance of Executive’s
duties to the Company.

 

(d) Non-Disparagement.
Executive agrees that he shall not, directly or indirectly disparage, whether or not truthfully, the name or reputation of the
Company or any of its affiliates, including but not limited to, any officer, director, employee or shareholder (provided Executive
has had material dealings with such shareholder) of the Company or any of its affiliates;
provided that, nothing in this Section shall be construed to interfere with Executive’s right to engage in protected
concerted activity under the National Labor Relations Act. Upon Executive’s termination of employment, the Company shall
direct its senior officers and directors not to directly or indirectly disparage, whether or not truthfully, the name or reputation
of Executive. Notwithstanding this Section 6(d), nothing contained herein shall apply to statements made by Executive
or the Company (x) in the course of their responsibility to evaluate the performance and/or participate in any investigation of
the conduct or behavior of officers, employees and/or others, (y) as part of any judicial, administrative or other legal action
or proceeding, or (z) in rebuttal of false or misleading statements by others, and nothing shall be construed to limit or impair
the ability of Executive or the Company to provide truthful testimony in response to any validly issued subpoena or to file pleadings
or respond to inquiries or legal proceedings by any government agency to the extent required by applicable law. These non-disparagement
obligations will cease to apply two (2) years after Executive’s termination of employment.

 

    7

     

    

 

(e) Enforcement.
In the event that Executive breaches or threatens to breach any provisions of Section 5 or this Section 6,
then, in addition to any other rights the Company may have, it shall be entitled to seek injunctive relief to enforce such provisions.
In the event that an actual proceeding is brought in equity to enforce the provisions of Section 5 or this Section
6, Executive shall not urge as a defense that there is an adequate remedy at law nor shall the Company be prevented from
seeking any other remedies that may be available to it nor shall the Company be required to post a bond.

 

(f) Remedies
Cumulative; Judicial Modification. Each of the rights and remedies enumerated in Section 6(e) shall be independent
of the others and shall be in addition to and not in lieu of any other rights and remedies available to the Company at law or in
equity. If any of the covenants contained in this Section 6, or any part of any of them, is hereafter construed or
adjudicated to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants or rights or remedies,
which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section
6 is held to be invalid or unenforceable because of the duration of such provision or the area covered thereby, the Parties
agree that the court making such determination shall have the power to reduce the duration and/or area of such provision and in
its reduced form such provision shall then be enforceable.

 

(g) Survival.
The provisions of this Section 6 shall survive any termination of this Agreement.

 

7. Representations
and Warranties.

 

(a) By
Executive. Executive hereby represents and warrants to the Company as follows:

 

(i) Neither
the execution or delivery of this Agreement nor the performance by Executive of his duties and other obligations hereunder conflict
with or constitute a default or breach of any covenant or obligation under (whether immediately, upon the giving of notice or lapse
of time or both) any prior employment agreement, contract, or other instrument to which Executive is a party or by which he is
bound.

 

(ii) Executive
has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other obligations
hereunder. This Agreement constitutes the legal, valid and binding obligation of Executive enforceable against him in accordance
with its terms. No approvals or consents of any persons or entities are required for Executive to execute and deliver this Agreement
or perform his duties and other obligations hereunder.

 

(iii) Executive
will not use any confidential information or trade secrets of any third Party in his employment by the Company in violation of
the terms of the agreements under which he had access to or knowledge of such confidential information or trade secrets.

 

(iv) Executive
has no knowledge of information that would cause the Company not to receive satisfactory results of Executive’s California
background check, as determined in good faith by the Company’s Board of Directors.

 

(b) By
The Company. The Company hereby represents and warrants to Executive that the Company has the full right and power to enter
and deliver this Agreement and to perform its obligations hereunder. This Agreement constitutes the legal, valid and binding obligation
of the Company enforceable against it in accordance with its terms. All approvals or consents required for the Company to validly
execute and deliver this Agreement and perform its obligations hereunder, including, without limitation, approval of the Board,
if required, have been obtained.

 

    8

     

    

 

8. Termination.

 

(a) Cause.
Executive’s employment hereunder may be terminated by the Company immediately for Cause. Any of the following actions by
Executive shall constitute “Cause”:

 

(i) The
willful failure, disregard or refusal by Executive to perform his material duties or obligations under this Agreement (other than
as a result of Executive’s mental incapacity or illness, as confirmed by medical evidence provided by a physician selected
by the Company);

 

(ii) Any
willful, intentional or grossly negligent act by Executive having the effect of materially injuring (whether financially or otherwise)
the business or reputation of the Company or any of its affiliates (other than acts that were performed in a good faith attempt
to advance the business interests of the Company);

 

(iii) Executive’s
conviction of any felony involving moral turpitude (including entry of a guilty or nolo contendere plea);

 

(iv) The
Executive’s qualification as a “bad actor,” as defined by 17 CFR 230.506(a);

 

(v) The
good faith determination by the Board, after a reasonable and good-faith investigation by the Company that Executive engaged in
some form of harassment prohibited by law (including, without limitation, harassment on the basis of age, sex or race) unless Executive’s
actions were specifically directed by the Board;

 

(vi) Any
material misappropriation or embezzlement by Executive of the property of the Company or its affiliates (whether or not a misdemeanor
or felony); or

 

(vii) Breach
by Executive of any material provision of this Agreement that is materially injurious to the Company.

 

Notwithstanding the foregoing,
in no event shall Cause exist unless the Company’s Board has made a formal determination of Cause by majority vote and provided
Executive with ten (10) days advance notice followed by the right to be heard in front of the entire Board followed by a second
majority vote finding that Cause still exists. Such meeting of the Board can occur in person or via teleconference. If the circumstances
surrounding Cause are reasonably curable, then the Executive shall have the right to cure those circumstances over the next twenty
(20) days. If the circumstances are not curable or if those circumstances still exist after the cure period has expired, then (and
only then) shall Cause be deemed to exist for purposes of this Agreement.

 

(b) Death.
Executive’s employment hereunder shall be terminated upon Executive’s death.

 

(c) Disability.
The Company may terminate Executive’s employment hereunder due to Executive’s “Disability” (defined below)
while Executive is so Disabled. For purposes of this Agreement, a termination due to Executive’s “Disability”
shall be deemed to have occurred if the Executive has not been able to perform his material duties for one hundred eighty (180)
days in a three hundred sixty five (365) day period.

 

    9

     

    

 

(d) Good
Reason. Executive may terminate his employment hereunder for “Good Reason” (as defined below) pursuant to the procedures
set forth in this Section 8(d). In order for Executive to resign for Good Reason, Executive must provide written
notice to the Board of the existence of the Good Reason condition within sixty (60) days of the initial existence of such Good
Reason condition. Upon receipt of such notice, the Company will have thirty (30) days during which it may attempt to remedy the
Good Reason condition. If so remedied, Executive may not resign for Good Reason based on such condition. If the Good Reason condition
is not remedied within such thirty (30) day period, Executive may resign based on the Good Reason condition specified in the notice
effective no later than thirty (30) days following the expiration of the thirty (30) day cure period. The term “Good
Reason” shall mean any of the following occurring without the Executive’s consent:

 

(i) any
material breach of this Agreement by the Company;

 

(ii) any
material reduction by the Company of Executive’s duties, responsibilities, or authority;

 

(iii) a
material reduction in Executive’s annual Base Salary unless (i) all officers and/or members of the Company’s executive
management team experience an equal or greater percentage reduction in annual base salary and/or total compensation;
and (ii) Executive’s Base Salary and/or total compensation reduction is no greater than twenty-five (25) percent;
or

 

(iv) a
material reduction in Executive’s target bonus level unless: (i) all officers and/or members of the Company’s executive
management team experience an equal or greater percentage reduction related to target bonus levels;
and (ii) Executive’s target bonus level reduction is no greater than twenty-five (25) percent.

 

(e) Convenience.
Either Party may terminate Executive’s employment hereunder for any reason or no reason at any time upon sixty (60) days
written notice of termination to the other Party, which notice shall specify the termination date, or by providing a Notice of
Nonrenewal to the other Party pursuant to the terms of Section 2.

 

9. Compensation
upon Termination.

 

In the event Executive’s
employment is terminated, the Company shall pay to Executive the Base Salary and benefits otherwise payable to him under Section
4 through the last day of his actual employment by the Company, along with any reimbursable business expenses subject to
Company policy and any amounts due under any benefit plan or program in accordance with its terms (together, the “Accrued
Compensation”). Except for the Accrued Compensation, rights to indemnification and directors’ and officers’
liability insurance, and as otherwise required by law, Executive will have no further entitlement hereunder to any other compensation
or benefits from the Company except as expressly provided below:

 

(a) Death
or Disability. If Executive’s employment is terminated as a result of his death or Disability, the Company shall pay
to Executive or to Executive’s estate, as applicable, the Accrued Compensation. In addition, Executive shall receive the
bonus due for any completed fiscal year to the extent that such bonus has not yet been paid (including timing of payment, the “Prior
Year Bonus”).

 

(b) Cause.
If Executive’s employment is terminated by the Company for Cause, Executive shall not be entitled to receive any payments
or benefits other than the Accrued Compensation, rights to indemnification and directors’ and officers’ liability insurance
and as otherwise required by law. All outstanding Awards and Stock Options that are granted on or after the Commencement Date,
whether or not vested, shall be forfeited to the Company as of such date.

 

    10

     

    

 

(c) Other
than for Cause, Non-Renewal, Death or Disability. If the Company terminates Executive’s employment, other than as a result
of Executive’s death or Disability, other than by Notice of Nonrenewal and other than for Cause, or if Executive terminates
Executive’s employment for Good Reason, then conditioned upon Executive executing and not revoking a Release (as defined
below) following such termination, the Company will provide to Executive the following separation benefits:

 

(i) Payment
of the Accrued Compensation and Prior Year Bonus, rights to indemnification and directors’ and officers’ liability
insurance and any rights or privilege otherwise required by law,

 

(ii) Payment
to Executive of an amount equal to nine (9) months of his Base Salary, which shall be paid over a period of nine (9) months following
the termination date,

 

(iii) Payment
to Executive of a prorated annual bonus for the year in which the termination date occurs, based on the actual achievement of the
objectives referenced in Section 4(b). The prorated bonus will be calculated as the annual bonus based on performance,
multiplied by a fraction, the numerator of which is the number of days preceding the termination date in the year of termination
and the denominator of which is three hundred sixty five (365) (the “Prorated Bonus”).

 

(iv) If
Executive timely elects continued health insurance coverage under COBRA, payment to Executive monthly of a portion of the premium
necessary to continue such coverage for Executive and Executive’s eligible dependents that is equal to the portion paid for
by the Company at the date of termination, until the conclusion of the time when Executive is receiving continuation of Base Salary
payments under Section 9(c)(ii) above or until Executive becomes eligible for group health insurance coverage under
another employer’s plan, whichever occurs first, provided however that the Company has the right to terminate such payment
of COBRA premiums on behalf of Executive and instead pay Executive a lump sum amount equal to the COBRA premium amount described
above times the number of months remaining in the specified period if the Company determines in its discretion that continued payment
of the COBRA premiums is or may be discriminatory under Section 105(h) of the Code, consistent with Section 409A of the Code, and

 

(v) All
Awards and Stock Options that are scheduled to vest on or before the next succeeding anniversary of the date of termination shall
be accelerated and deemed to have vested as of the termination date; provided that, for the avoidance of doubt, any performance
based Awards or Stock Options (including the Milestone Options) whose vesting requirements have not been successfully met as of
the date of Executive’s termination of employment or resignation with Good Reason will not accelerate. All Stock Options
that have vested (or been deemed pursuant to the immediately preceding sentence to have vested) as of the date of Executive’s
termination shall remain exercisable until the earlier of the expiry of ninety (90) days following such termination or the termination
date applicable under the grant.

 

The separation benefits
set forth above are conditioned upon Executive executing a release of claims against the Company, its parents, subsidiaries and
affiliates and each of its officers, directors, employees, agents, successors and assigns in substantially the form attached hereto
as Exhibit C (the “Release”) within the time specified therein, which Release is not revoked within
any time period allowed for revocation under applicable law. The salary continuation described in Section 9(c)(ii)
above will be payable to Executive over time in accordance with the Company’s payroll practices and procedures beginning
on the sixtieth (60th) day following the termination of Executive’s employment with the Company, provided that the Company,
in its sole discretion but in accordance with Internal Revenue Code Section 409A, may begin the payments earlier. The Prorated
Bonus described in Section 9(c)(iii) above shall be paid at the date on which the annual bonus would have been paid
had Executive continued in employment, and the COBRA payments Section 9(c)(iv) above shall be paid monthly beginning
on the date on which the salary continuation commences.

 

    11

     

    

 

(d) By
Notice of Non-Renewal; Termination without Good Reason. If, pursuant to Section 8(e), Executive terminates his
employment hereunder by written notice of termination without Good Reason or if either Party terminates Executive’s employment
by providing a Notice of Nonrenewal to the other Party, Executive shall not be entitled to receive any payments or benefits other
than the Accrued Compensation, the Prior Year’s Bonus, rights to indemnification and directors’ and officers’
liability insurance and as otherwise required by law.

 

(e) This
Section 9 sets forth the only obligations of the Company with respect to the termination of Executive’s employment
with the Company, and Executive acknowledges that, upon the termination of his employment, he shall not be entitled to any payments
or benefits which are not explicitly provided in this Section 9, except as required by law or the terms of another
employee plan, program or arrangement covering him. Executive acknowledges and agrees that upon the termination of his employment
with the Company, regardless of the reason or grounds therefor, he shall resign from any board, organization or foundation wherein
Executive sits or belongs as a representative of the Company.

 

(f) The
obligations of the Company that arise under this Section 9 shall survive the expiration or earlier termination of
this Agreement.

 

10. Corporate
Transaction.

 

(a) Corporate
Transaction Defined. The term “Corporate Transaction” shall have the same meaning as defined in the
Company’s 2019 Omnibus Stock Incentive Plan, as in effect on the date of this Agreement.

 

(b) Consequence
upon Executive’s Termination Without Cause or Executive’s Resignation With Good Reason. Upon Executive’s
termination of employment without Cause or Executive’s resignation of employment with Good Reason within twenty-four (24)
months after a Corporate Transaction, the Company shall provide Executive the following separation benefits:

 

(i) Payment
of the Accrued Compensation, the Prior Year Bonus, rights to indemnification and directors’ and officers’ liability
insurance and any rights or privilege otherwise required by law,

 

(ii) Payment
to Executive of an amount equal to nine (9) months of his Base Salary and full target bonus as in effect for the year of termination,
which shall be paid over a period of nine (9) months following the termination date,

 

(iii) 
Payment to Executive of the Prorated Bonus,

 

(iv) If
Executive timely elects continued health insurance coverage under COBRA, payment to Executive monthly of a portion of the premium
necessary to continue such coverage for Executive and Executive’s eligible dependents that is equal to the portion paid for
by the Company at the date of termination, until the conclusion of the time when Executive is receiving continuation of Base Salary
and bonus payments under Section 9(c)(ii) above or until Executive becomes eligible for group health insurance coverage
under another employer’s plan, whichever occurs first, provided however that the Company has the right to terminate such
payment of COBRA premiums on behalf of Executive and instead pay Executive a lump sum amount equal to the COBRA premium amount
described above times the number of months remaining in the specified period if the Company determines in its discretion that continued
payment of the COBRA premiums is or may be discriminatory under Section 105(h) of the Code, consistent with Section 409A of the
Code, and

 

    12

     

    

 

(v) All
unvested Awards and unvested Stock Options held by Executive shall be accelerated and deemed to have vested as of the date of the
Executive’s termination of employment. All Stock Options that have vested (or been deemed pursuant to the immediately preceding
sentence to have vested) as of the date of Executive’s termination of employment shall remain exercisable until the earlier
of the expiry of twelve (12) months following such termination or the termination date applicable under the grant.

 

The separation benefits
set forth above are conditioned upon Executive executing a Release within the time specified therein, which Release is not revoked
within any time period allowed for revocation under applicable law. The salary and bonus continuation described in Section
10(b)(ii) above will be payable to Executive over time in accordance with the Company’s payroll practices and procedures
beginning on the sixtieth (60th) day following the termination of Executive’s employment with the Company, provided that
the Company, in its sole discretion but in accordance with “Section 409A” (defined below), may begin the payments earlier.
The Prorated Bonus described in Section 10(b)(iii) above shall be paid at the date on which the bonus would have
been paid had Executive continued in employment, and the COBRA payments described in Section 10(b)(iv) above shall
be paid monthly beginning on the date on which the salary continuation commences.

 

(c) Potential
Adjustments due to Tax Implications. Notwithstanding anything in this Agreement or any other agreement between Executive and
the Company to the contrary, but subject to this Section 10(c), the Company will effectuate the acceleration contemplated
under Section 10(b) and will make the payments and other acceleration of benefits under this Agreement and other
compensatory arrangements without regard to whether Section 280G of the Code would limit or preclude the deductibility of such
payments or benefits. However, if reducing or eliminating any payment and/or other benefit (including the vesting of his options
or other equity compensation) would increase the “Total After-Tax Payments” (defined below), then the amounts payable
to Executive will be reduced or eliminated as follows (or in such other manner as Executive may specify at the applicable time
if permitted to do so without violation of Internal Revenue Code Sections 280G, 409A and 4999) to the extent necessary to maximize
such Total After-Tax Payments:

 

(i) first,
by reducing or eliminating any cash payments or other benefits (other than the vesting of any options or stock) and

 

(ii) second,
by reducing or eliminating the vesting of options and stock that occurs as a result of a Corporate Transaction or other event covered
by Section 280G of the Code in reverse order of vesting and with grants whose parachute value is calculated without regard to Treasury
Regulations 280G-1 Q&A 24(c) being reduced prior to those subject to Q&A 24(c).

 

The Company’s
independent, certified public accounting firm will determine whether and to what extent payments or vesting are required to be
reduced or eliminated in accordance with the foregoing. If there is ultimately determined to be an underpayment of or overpayment
to Executive under this provision, the amount of such underpayment or overpayment will be immediately paid to Executive or refunded
by him, as the case may be, with interest at the applicable federal rate under the Code. The term “Total After Tax
Payments” means the total value of all “parachute payments” (as that term is defined in Section 280G(b)(2)
of the Code) made to Executive or for his benefit (whether made under the Agreement or otherwise), after reduction for all applicable
federal taxes (including, without limitation, the tax described in Section 4999 of the Code). The cost of the accountant shall
be paid by the Company and the accountant shall deliver to the parties its calculations in a form that can be relied upon for filing
of tax returns. The calculations made pursuant to this section shall be made by allocating the full summary compensation table
value (from the latest filed proxy) or an estimate thereof of the Executive’s annual total compensation to the noncompete
set forth in this Agreement.

 

    13

     

    

 

11. Indemnification.

 

The Company shall defend
and indemnify Executive regard to his capacities with the Company, its affiliates and its benefit plans to the fullest extent permitted
under the Delaware General Corporate Law (the “DGCL”). The Company shall also maintain a policy for indemnifying
its officers and directors, including but not limited to Executive, for all actions permitted under the DGCL taken in good faith
pursuit of their duties for the Company, including, but not limited to, the obtaining of an appropriate level of directors and
officers liability insurance coverage and including such provisions in the Company’s bylaws or certificate of incorporation,
as applicable and customary. Executive shall be designated as a named insured on such directors and officers liability insurance
policy. Executive’s rights to, and the Company’s obligation to provide, indemnification shall survive termination of
this Agreement.

 

12. Compliance
with Code Section 409A.

 

(a) Intent
of the Parties. The intent of the Parties is that the payments, compensation and benefits under this Agreement will be exempt
from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated
thereunder (collectively “Section 409A”) and, in this connection, the Agreement shall be interpreted
to be exempt or in compliance with Section 409A. Further, if any benefit or payment payable under this Agreement is deemed to not
comply with Section 409A, the Company and Executive agree to renegotiate in good faith any such benefit or payment (including,
without limitation, as to the timing of any severance payments payable hereunder) so that either (i) Section 409A will not apply
or (ii) compliance with Section 409A will be achieved; provided, however, that any resulting renegotiated terms shall provide
to Executive the after-tax economic equivalent of what otherwise has been provided to Executive pursuant to the terms of this Agreement,
and provided further, that any deferral of payments or other benefits shall be only for such time period as may be required to
comply with Section 409A.

 

(b) Potential
Delay of Payment(s) and Adjustments. For the avoidance of doubt, the Parties intend that payments of the separation benefits
set forth in Section 9 and Section 10 above satisfy, to the greatest extent possible, the exemptions
from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9).
If any payment, compensation or other benefit provided to Executive in connection with his separation from service is determined,
in whole or in part, to constitute “nonqualified deferred compensation” within the meaning of Section 409A and Executive
is a “specified employee” within the meaning of Section 409A, no part of such payments shall be paid before the day
that is six (6) months plus one (1) day after the termination date or his earlier death (the “New Payment Date”).
The aggregate of any payments that otherwise would have been paid to Executive during the period between the termination date and
the New Payment Date shall be paid to Executive in a lump sum on such New Payment Date. Thereafter, any payments that remain outstanding
as of the day immediately following the New Payment Date shall be paid without delay over the time period originally scheduled,
in accordance with the terms of this Agreement.

 

(c) Separation
from Service. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under Section
9 or Section 10 above that constitute “deferred compensation” within the meaning of Section 409A
will not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a
“separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)), unless the Company
reasonably determines that such amounts may be provided to Executive without causing Executive to incur additional tax under Section
409A.

 

    14

     

    

 

(d) Installments;
Year of Payment. If any payment, compensation or other benefit required by the Agreement is to be paid in a series of installment
payments, each individual payment in the series shall be considered a separate payment for purposes of Section 409A. In no event
may Executive designate the year of payment of a benefit under this Agreement, except in accordance with Section 409A.

 

13. Miscellaneous.

 

(a) Governing
Law. This Agreement and all questions relating to its validity, interpretation, performance, remediation, and enforcement (including,
without limitation, provisions concerning limitations of actions) shall be governed by and construed in accordance with the substantive
laws of the State of Delaware, notwithstanding any choice-of-law doctrines of that jurisdiction or any other jurisdiction that
ordinarily would or might cause the substantive law of another jurisdiction to apply.

 

(b) Company
Policies. All incentive compensation under this Agreement shall be subject to the terms of any clawback, recoupment or other
policies approved by the Board and applicable to executive officers of the Company.

 

(c) Personal
Jurisdiction. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY ACTION OR PROCEEDING RELATING IN ANY WAY TO THIS AGREEMENT
MAY ONLY BE BROUGHT AND ENFORCED IN THE STATE OR FEDERAL COURTS LOCATED IN UNION COUNTY, NEW JERSEY, TO THE EXTENT SUBJECT MATTER
JURISDICTION EXISTS THEREFORE. THE PARTIES IRREVOCABLY SUBMIT TO THE JURISDICTION OF SUCH COURTS IN RESPECT OF ANY SUCH ACTION
OR PROCEEDING. THE PARTIES IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT THEY MAY NOW
OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH ACTION OR PROCEEDING IN SUCH COURTS, AS WELL AS ANY CLAIM THAT ANY SUCH ACTION
OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN ANY INCONVENIENT FORUM.

 

(d) Service
of Process. THE PARTIES FURTHER IRREVOCABLY CONSENT TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN THE
MANNER AND TO THE ADDRESS SPECIFIED IN SECTION 13(i) OF THIS AGREEMENT.

 

(e) Waiver of Jury Trial.
EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED
IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY IN THE NEGOTIATION, ADMINISTRATION,
PERFORMANCE AND ENFORCEMENT THEREOF. EACH OF THE PARTIES HERETO FURTHER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THIS WAIVER
WITH ITS LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.
THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY
SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY
BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

 

(f) Assignment.
This Agreement, and Executive’s rights and obligations hereunder, may not be assigned by Executive. The Company may assign
its rights, together with its obligations, hereunder only in connection with any sale, transfer or other disposition of all or
substantially all of its business or assets and to an assignee who assumes such obligations by law or in writing. Subject to the
foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto, and their respective heirs, legal
representatives, successors and assigns.

 

    15

     

    

 

(g) Amendment.
This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement duly executed
by the Parties.

 

(h) Waiver.
The failure of either Party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement
shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions
shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either Party shall be
effective for any purpose whatsoever unless such waiver is in writing and signed by such Party. Unless the written waiver instrument
expressly provides otherwise, no waiver by a Party of any right or remedy or breach by the other Party in any particular instance
shall be construed to apply to any right, remedy or breach arising out of or related to a subsequent instance.

 

(i) Notices.
All notices, demands or other communications desired or required to be given by a Party to the other Party shall be in writing
and shall be deemed effectively given upon (i) personal delivery to the Party to be notified, (ii) upon confirmation of receipt
of fax or other electronic transmission, (iii) one business day after deposit with a reputable overnight courier, prepaid for priority
overnight delivery, or (iv) five days after deposit with the United States Postal Service, postage prepaid, certified mail, return
receipt requested, in each case to the Party to be notified at the Company’s principal executive officers in the case of
the Company and at the latest address of the Executive on the books of the Company in the case of the Executive; or to such
other addresses and to the attention of such other individuals as either Party shall have designated to the other by notice given
in the foregoing manner.

 

(j) Entire
Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter hereof,
and supersedes all prior agreements, arrangements and understandings, written or oral between the Parties, relating to the subject
matter hereof.

 

(k) Affiliate
and Control Defined. As used in this Agreement, the term “affiliate” of a specified Person shall
mean and include any Person controlling, controlled by or under common control with the specified Person. A Person shall be deemed
to “control” another Person if such first Person possesses directly or indirectly the power to direct,
or cause the direction of, the management and policies of the second Person, whether through the ownership of voting securities,
by contract or otherwise.

 

(l) Captions,
Headings and Cross-References. The section headings contained herein are for reference purposes and convenience only and shall
not in any way affect the meaning or interpretation of this Agreement. Except as expressly set forth otherwise, all cross-references
to sections refer to sections of this Agreement.

 

(m) Severability.
In addition to, and not in conflict with, the provisions of Sections 6(b) and 6(f), the Parties agree that each and
every provision of this Agreement shall be deemed valid, legal and enforceable in all jurisdictions to the fullest extent possible.
Any provision of this Agreement that is determined to be invalid, illegal or unenforceable in any jurisdiction shall, as to that
jurisdiction, be adjusted and reformed rather than voided, if possible, in order to achieve the intent of the Parties. Any provision
of this Agreement that is determined to be invalid, illegal or unenforceable in any jurisdiction which cannot be adjusted and reformed
shall for the purposes of that jurisdiction, be voided. Any adjustment, reformation or voidance of any provisions of this Agreement
shall only be effective in the jurisdiction requiring such adjustment or voidance, without affecting in any way the remaining provisions
of this Agreement in such jurisdiction or adjusting, reforming, voiding or rendering that provision or any other provision of this
Agreement invalid, illegal or unenforceable in any other jurisdiction.

 

    16

     

    

 

(n) Counterpart
Execution. This Agreement may be executed in one or more counterparts each of which shall be an original document and all of
which together shall constitute one and the same instrument. The Parties acknowledge that this Agreement may be executed and delivered
by means of electronic signatures and that use and acceptance of electronic signatures to bind the Parties represents the voluntary
agreement and intention of the Parties to conduct this transaction by electronic means. The Parties agree that execution and delivery
by electronic means will have the same legal effect as if signatures had been manually written on this Agreement. This Agreement
will be deemed lawfully executed by the Parties by such action for purposes of any statute or rule of law that requires this Agreement
to be executed by the Parties to make the mutual promises, agreements and obligations of the Parties set forth herein legally enforceable.
Facsimile and .pdf exchanges of signatures will have the same legal force and effect as the exchange of original signatures. THE
PARTIES HEREBY WAIVE ANY RIGHT TO RAISE ANY DEFENSE OR WAIVER BASED UPON EXECUTION OF THIS AGREEMENT BY MEANS OF ELECTRONIC SIGNATURES
IN ANY PROCEEDING ARISING UNDER OR RELATING TO THIS AGREEMENT. The Parties agree that the legal effect, validity and enforceability
of this Agreement will not be impaired solely because of its execution in electronic form or that an electronic record was used
in its formation. The Parties acknowledge that they are capable of retaining electronic records of this transaction.

 

IN WITNESS WHEREOF,
the Parties hereto have executed this Employment Agreement as of the date set forth above.

 

Signature page follows.

 

    17

     

    

 

	CORMEDIX INC.	 	EXECUTIVE
	 	 	 
	/s/ Khoso Baluch	 	/s/ Dr. Matt David
	Date: May 11, 2020	 	Dr. Matt David
	 	 	 
	 	 	Date: May 11, 2020

 

    18

     

    

 

EXHIBIT A

 

PERFORMANCE MILESTONES

 

[***]

 

    19

     

    

 

EXHIBIT B

 

PRIOR INVENTIONS

 

    20

     

    

 

EXHIBIT C

 

RELEASE

 

Separation
Agreement and Release

 

This Separation Agreement and Release (the “Agreement”)
sets forth the terms of your separation from employment with CorMedix Inc. (the "Company"). If you understand and agree
with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document
representing the entire agreement between you and the Company regarding the subjects it covers. We will refer to this document
as the "Agreement."

 

Termination Date. Your last day of work with the Company
will be XXX.

 

Consideration. The Company will pay you [DESCRIBE SEVERANCE
PAY AND PAYMENT DATES], if you sign and do not revoke this Agreement. The severance pay is provided pursuant to the terms of the
Employment Agreement dated [______], 2020 between you and the Company (the “Employment Agreement”).

 

Release of Claims. In exchange for the payment(s) described
in the Consideration clause, you hereby waive all claims available under federal, state or local law against the Company, its parent,
partners and affiliates, and its and their respective directors, officers, employees, agents, insurers and reinsurers, and employee
benefit plans (and the trustees, administrators, fiduciaries, insurers and reinsurers of such plans) past, present, and future,
their heirs, executors, administrators, representatives, successors and assigns arising out of your employment with the Company
or the termination of that employment, including but not limited to all claims arising under the Americans with Disabilities Act,
the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Equal Pay Act, the Genetic Information Non-discrimination
Act, the Family and Medical Leave Act, Section 1981 of U.S.C, Title VII of the Civil Rights Act, and you also hereby waive your
rights under the following statutes to the fullest extent permissible under applicable state and local laws including, but not
limited to the New Jersey Law Against Discrimination, New Jersey Equal Pay Act, New Jersey Civil Rights Law, New Jersey Security
and Financial Empowerment Act, New Jersey Conscientious Employee Protection Act, New Jersey Family Leave Act, New Jersey Wage and
Hour Law, New Jersey WARN Laws, retaliation provisions of New Jersey Workers' Compensation Law, as well as wrongful termination
claims, breach of contract claims, discrimination claims, harassment claims, retaliation claims, whistleblower claims (to the fullest
extent they may be released under applicable law), defamation or other tort claims, and claims for attorneys’ fees and costs.
You are not waiving your right to vested benefits under the written terms of the Company 401(k) Plan, claims for unemployment or
workers’ compensation benefits, any medical claim or any judgment or monetary awards or settlements that may arise related
to medical benefits under the group health plan sponsored by the Company, claims arising after the date on which you sign this
Agreement, claims that are not otherwise waivable under applicable law, or claims to indemnification under Section 11 of the Employment
Agreement. You acknowledge that you have not made any claims or allegations related to sexual harassment or sexual abuse and none
of the payments set forth in this Agreement are related to sexual harassment or sexual abuse.

 

    21

     

    

 

Medicare Disclaimer. You represent that you are not a
Medicare Beneficiary as of the time you enter into this Agreement.

 

Limit on Disclosures. You shall not disclose or cause
to be disclosed the terms of this Agreement to any person (other than your spouse or domestic/civil union partner, attorney and
tax advisor), except pursuant to a lawful subpoena, as set forth in the Reports to Government Entities clause below, or as otherwise
permitted by law. This provision is not intended to restrict your legal right to discuss the terms and conditions of your employment.

 

Restrictive Covenants. You agree
to comply with the confidentiality, inventions, non-competition, non-solicitation and non-disparagement provisions of the Employment
Agreement according to their terms.

 

Reports to Government Entities. Nothing in this Agreement,
including the Limit on Disclosures or Release of Claims clauses, restricts or prohibits you from initiating communications directly
with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations
of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or
a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National
Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector
General (collectively, the "Regulators"), or from making other disclosures that are protected under the whistleblower
provisions of state or federal law or regulation. However, to the maximum extent permitted by law, you are waiving your right to
receive any individual monetary relief from the Company or any others covered by the Release of Claims resulting from such claims
or conduct, regardless of whether you or another party has filed them, and in the event you obtain such monetary relief the Company
will be entitled to an offset for the payments made pursuant to this Agreement. This Agreement does not limit your right to receive
an award from any Regulator that provides awards for providing information relating to a potential violation of law. You do not
need the prior authorization of the Company to engage in conduct protected by this paragraph, and you do not need to notify the
Company that you have engaged in such conduct.

 

Please take notice that federal law provides criminal and civil
immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney,
a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1)
and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit
for retaliation for reporting a suspected violation of the law.

 

Non-Admission of Liability.  Nothing in this Agreement
is an admission of any wrongdoing, liability or unlawful activity by you or by the Company.

 

No Other Amounts Due. You acknowledge that the Company
has paid you all wages, salaries, bonuses, benefits and other amounts earned and accrued, less applicable deductions, and that
the Company has no obligation to pay "any additional amounts other than the payments described in the Consideration Clause
of this Agreement.

 

    22

     

    

 

Addendum to General Release for Age Claims. In addition
to all other claims released for the payment(s) described in the Consideration clause, you hereby waive all claims available against
the Company and the directors, officers, employees, employee benefit plans and agents of the Company arising out of your employment
with the Company or the termination of that employment under the Age Discrimination in Employment Act and the Older Workers Benefit
Protection Act.

 

Acknowledgement of Voluntariness and Time to Review. 
You acknowledge that:

 

		●	you read this Agreement and you understand it;

		●	you are signing this Agreement voluntarily in order to release your claims against the Company in exchange for payment that
is greater than you would otherwise have received;

		●	you are signing this Agreement after the date of your separation from the Company and you were offered at least 21 days to
consider your choice to sign this Agreement;

		●	the Company advises you to consult with an attorney;

		●	you know that you can revoke this Agreement within 7 days of signing it and that the Agreement does not become effective until
that 7-day period has passed. To revoke, contact xxx; and

		●	you agree that changes to this Agreement before its execution, whether material or immaterial, do not restart your time to
review the Agreement.

 

Duty of Cooperation. You agree to cooperate fully and
in a timely manner with the Company and its counsel with respect to any matter (including any litigation, investigation or governmental
proceeding) which relates to your employment with the Company. This cooperation may include appearing from time-to-time for conferences
and interviews, and providing the officers of the Company and its counsel with the full benefit of your knowledge with respect
to any such matter. The Company will request such cooperation with due regard to your personal and professional commitments. Subject
to the Company's prior approval, the Company will reimburse you for reasonable out-of-pocket costs and expenses such as travel
expenses, and will endeavor to set meeting times that are mutually agreeable.

 

Governing Law. This Agreement shall be governed by the
laws of New Jersey without reference to that jurisdiction's choice of law rules.

 

Return of Records and Equipment. You agree that you have
returned all Company property, including but not limited to keys, ID card, cell phone, PDA, and Company documents and information
(either hard copy or electronic) other than records related solely to your own compensation or benefits.

 

Severability. In the event a court, arbitrator or other
entity with jurisdiction determines that any portion of this Agreement (other than the general release clause) is invalid or unenforceable,
the remaining portions of the Agreement shall remain in full force and effect.

 

[Signature Page Follows]

 

    23

     

    

 

The Company hereby advises you to consult with an attorney prior
to signing this Agreement. You acknowledge that you have had a reasonable amount of time to consider the terms of this Agreement
and you sign it with the intent to be legally bound.

 

	CorMedix Inc.	 	 	 
	 	 	 	 
	 	 	Date:	 
	 	 	 	 
	Employee:	 	 	 
	 	 	 	 
	 	 	Date:	 

 

[TO BE SIGNED AFTER TERMINATION OF
EMPLOYMENT]

 

 

24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]